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Abstract
Background: Liquid-state specimen carriers are inadequate for sample transportation in large-scale screening
projects in low-resource settings, which necessitates the exploration of novel non-hazardous solid-state alternatives.
Studies investigating the feasibility and accuracy of a solid-state human papillomavirus (HPV) sampling medium in
combination with different down-stream HPV DNA assays for cervical cancer screening are needed.
Methods: We collected two cervical specimens from 396 women, aged 25–65 years, who were enrolled in a
cervical cancer screening trial. One sample was stored using DCM preservative solution and the other was applied
to a Whatman Indicating FTA Elute® card (FTA card). All specimens were processed using three HPV testing
methods, including Hybrid capture 2 (HC2), careHPV™, and Cobas®4800 tests. All the women underwent a rigorous
colposcopic evaluation that included using a microbiopsy protocol.
Results: Compared to the liquid-based carrier, the FTA card demonstrated comparable sensitivity for detecting high
grade Cervical Intraepithelial Neoplasia (CIN) using HC2 (91.7 %), careHPV™ (83.3 %), and Cobas®4800 (91.7 %) tests.
Moreover, the FTA card showed a higher specificity compared to a liquid-based carrier for HC2 (79.5 % vs. 71.6 %,
P = 0.015), comparable specificity for careHPV™ (78.1 % vs. 73.0 %, P > 0.05), but lower specificity for the Cobas®4800
test (62.4 % vs. 69.9 %, P = 0.032). Generally, the FTA card-based sampling medium’s accuracy was comparable with
that of liquid-based medium for the three HPV testing assays.
Conclusions: FTA cards are a promising sample carrier for cervical cancer screening. With further optimization, it
can be utilized for HPV testing in areas of varying economic development.
Keywords: Whatman Indicating FTA Elute® card (FTA card), Cervical cancer screening, careHPV™, Cobas®4800,
Hybrid capture 2 (HC2)
Background
Cervical Cancer is the fourth most common cancer of
women worldwide. An estimated 528,000 new cases and
266,000 deaths from cervical cancer occur annually,
among which 85 % occur in developing countries. China,
a developing country with high cervical cancer incidence
(7.5/100,000) and mortality (3.4/100,000), bears a sub-
stantial burden of cervical disease [1, 2].
Current evidence shows that persistent infection with
carcinogenic human papillomavirus (HPV) types is the
cause of virtually all cervical cancer [3]. Consequently,
HPV DNA testing was explored as one of the primary
cervical cancer screening methods in several countries
[4]. In developing countries like China, where critical
infrastructure is not available, screening by gynecologists
and cytologists is generally inefficient and unworkable.
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Expanding the coverage of objective HPV testing methods
is a more expeditious and effective way to introduce large-
scale of cervical cancer screening. Combining cervical
sample collection with regional or centralized HPV detec-
tion could be an efficient way to increase screening cover-
age in such areas. However, most current HPV testing
methods utilize a liquid-based sample carrier, which is
limited by large sample volumes, risk of leakage, and
challenges with storage and transportation, especially in
remote rural areas.
Solid-state specimen carriers, such as the Whatman
Indicating FTA Elute® card (FTA card, GE Healthcare,
Buckinghamshire, UK), provide an alternative sampling
medium for DNA sample collection. FTA cards provide
a cost effective room temperature method for collecting,
shipping, archiving and processing nucleic acids from a
wide variety of biological samples. The cards contain an
inert dye that changes from purple to white indicating
the location of a clear, colorless sample. Moreover, indi-
cating FTA Elute cards facilitate rapid purification of nu-
cleic acids in less than 30 min per sample and provide
DNA in solution for multiple amplification reactions
with high stability. There is evidence that genomic DNA
stored on FTA cards at room temperature for more than
17.5 years still can be successfully amplified by PCR.
FTA cards have been used in forensic science for DNA
sample collection and storage for decades, but it has
only recently been explored as an alternative to current
liquid-based sampling mediums for cervical cancer
screening [5–9].
A few studies have investigated the FTA cards with
PCR-based detection methods or a single HPV DNA
testing method with high clinical sensitivity and specifi-
city [5, 9–12]. However, no published study has made a
direct comparison of FTA cards and liquid sampling
medium using the predominant clinical HPV testing
methods.
Therefore, our project sought to investigate the feasi-
bility of using FTA cards as an HPV sampling medium
for cervical cancer screening. We also explored the com-




Samples were collected among women enrolled in
“LCMCCSS”, a large population-based screening trial in
rural China, which was a collaboration between the
Cancer Institute, Chinese Academy of Medical Sciences
(CICAMS) and the Program for Appropriate Technology
in Health (PATH) [13, 14]. Eligible women were ages
25–65 years, not pregnant and did not have a history of
diagnosed Cervical Intraepithelial Neoplasia (CIN), cer-
vical cancer, or hysterectomy. After a socio-demographic
questionnaire survey, each woman provided one self-
collected and two clinician-collected specimens. The
self-collected specimen and one clinician-collected spe-
cimen were tested by careHPV™ and Hybrid Capture 2
(Qiagen, Gaithersburg, MD, USA); the other clinician-
collected specimen was tested for HPV16/18/45 E6
protein with the OncoE6™ Cervical test (Arbor Vita Cor-
poration, Sunnyvale, CA, USA). After sample collection,
women were screened by visual inspection with acetic
acid (VIA). One to two weeks later, women who tested
positive for any of the six screening tests performed
(VIA, HPV E6, and HC2 and careHPV™ on clinician-
collected and self-collected specimens) and approxi-
mately a 10 % random sample of women who tested
negative for all screening tests (screen-negative women)
were called back to undergo a second VIA and a rigor-
ous colposcopic evaluation. All colposcopically detected
abnormalities (acetowhite lesions) were biopsied. If the
colposcopic examination showed no lesion in a quadrant
but any of the screen results was positive, a random
biopsy was obtained at the squamocolumnar junction in
that quadrant at 2, 4, 8, or 10 o’clock. An endocervical
curettage (ECC) was performed after the cervical biop-
sies. Women who were screen negative and were with-
out any colposcopic indications of abnormality did not
undergo colposcopically-directed biopsies.
Sample collection
We conducted our study among women who returned
for colposcopy in LCMCCSS between May and June
2012. Recruitment was stopped when the target
sample size (n = 396) was reached. The population in-
cluded 207 women who were HPV positive, 17
women who were VIA positive (including 10 HPV
positive women) and 182 randomly selected normal
women. Ethics approval was obtained from the Ethics
Committee of Cancer Institute and Hospital, Chinese
Academy of Medical Sciences (Approval No. 12-040/574).
Written Informed consent was obtained from each sub-
ject. One liquid sample was collected by a physician using
a Conical Cervical Sampler (Qiagen, Gaithersburg, MD,
USA) and was stored in DCM preservative solution
(Qiagen, Gaithersburg, MD, USA). A second sample
was collected by a physician using a new Conical
Cervical Sampler and applied to an FTA card, which
will be referred to as the “solid sample” in this study.
All the samples were stored at room temperature and
analyzed in the CICAMS central laboratory. All the
women underwent a rigorous colposcopic evaluation
that included using a microbiopsy protocol as previ-
ously described [13, 15]. A CICAMS pathologist was
responsible for reporting the results and high grade
CIN case confirmation (see Fig. 1).
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Liquid sample detection
HC2, the first HPV DNA testing method approved by the
United States Food and Drug Administration for clinical
use, utilizes hybrid capture technology to detect 13 car-
cinogenic HPV genotypes. HC2 testing was conducted per
the manufacturer’s instruction, with one exception: 50 μl
of the DCM specimen was combined with 25 μl of the kit
denaturation reagent rather than combining 1000 μl of
STM specimen with 500 μl of the kit denaturation re-
agent. careHPV™ is a newly-developed and promising
screening system developed for low resource regions. Its
workflow is similar but simpler than the HC2 test with a
lower cost and simpler administration. careHPV™ testing
was conducted according to the manufacturer’s instruc-
tions as previously described [16]. A signal strength of 1.0
relative light units per positive control (rlu/pc) or greater
was considered positive for both tests. The Cobas®4800
test (Roche Molecular Systems, Pleasanton, CA) is a
widely-used, PCR-based testing method with high clinical
sensitivity and specificity [17, 18]. It can detect 14 types of
high-risk HPV and requires a lower number of DNA
copies as compared to the HC2 test. Since the manufac-
turer did not provide instructions for DCM-based sample
detection, CICAMS developed the workflow according to
several small pilot studies. DCM preservative solution was
diluted 10 times with sterilized PBS buffer, referring to
careHPV™ which had approved commercial instructions
for DCM samples. Thereafter, DNA extraction and PCR
amplification were performed according to the manufac-
turer’s instructions.
FTA card sample detection
In order to ensure a high degree of accuracy, CICAMS
and GE Healthcare performed pilot tests to develop
optimized protocols for use of FTA cards with the three
HPV assays. FTA cards were punched using a specifically
designed sterilized perforator (3-mm Harris Uni-Core
device; Whatman, GE Healthcare, Buckinghamshire, UK).
As HC2 and Cobas®4800 test used the same buffer, those
tests shared nine punched disks while the careHPV™
Fig. 1 Study Flow Chart.Note: CIN1 cervical intraepithelial neoplasia grade 1, CIN2 cervical intraepithelial neoplasia grade 2, FTA Whatman
Indicating FTA Elute® card, HC2 Hybrid capture 2
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assays used another six disks. This allowed us to obtain
the required testing concentration for each of the HPV
assays. The FTA card was chemically treated with propri-
etary reagents that lyse cells upon contact, causing the
release of nucleic acids. DNA was recovered from the
FTA elute matrix through a simplified elution process
using heat and water. Inhibitory components, such as
hemoglobin, were retained on the FTA elute matrix.
The six disks and nine disks were transferred into
separate 1.5-ml microfuge tubes. Five hundred microliter
of sterile water was added to each tube, and the tubes
were immediately pulse vortexed for 15 s. Water was
removed with a sterile fine-tip pipette. This process was
performed twice. Sixty microliter of DCM preservative
solution and 90 μl of DEPC water were added to each
tube. Both tubes were centrifuged for 30 s and trans-
ferred to a heating block at 95 °C for 30 min. During the
incubation period, both tubes were centrifuged for 30 s
every 10 min to minimize condensation. At the end of
heating process, both tubes were pulse vortexed approxi-
mately 30 s and centrifuged for 30 s. The eluted DNA
was placed into new microcentrifuge tubes and stored at
−80 °C until analysis. Finally, 50 μl of the eluate originat-
ing from the nine disks was used for HC2 and 25 μl was
used for Cobas®4800. Similarly, 50 μl of the eluate from
the six disks was used for the careHPV™ assay. There-
after, PCR amplification was performed to acquire final
results for Cobas®4800 test.
Statistical analysis
The primary objective of this study was to evaluate the
sensitivity and specificity of FTA card-based sampling
for the detection of CIN2+. According to previous stud-
ies, we assumed that the sensitivity of detecting CIN2+
would range from 0.85 to 0.96, the specificity of detect-
ing CIN2+ would range from 0.60 to 0.80, and the CIN2
+ prevalence would be approximately 4 %. Given these
parameters, we calculated a necessary sample size of 375
with an alpha of 0.05 and 80 % power [19]. Assuming a
5 % testing failure rate, a maximum of 395 women was
required. Demographic information such as age, marital
status, educational level, occupation, and sexual history
was quantified. The accuracy of each combination of
different sampling media and downstream HPV testing
methods was presented as sensitivity, specificity, and
positive and negative predictive values. Proportions were
compared using the Fisher’s exact test. SAS 9.2 was used
to analyze data (SAS Institute, Cary NC). The 95 % con-
fidence interval (95 % CI) was calculated using the Wald
test by OpenEpi Version 3 (www.OpenEpi.com), an open
source epidemiologic statistics for public health. Statis-
tical significance was assessed by two-tailed tests with an
alpha level of 0.05.
Results
Demographic information
A total of 3191 women were invited to participate in
screening through the LCMCCSS study in 2012, among
which 370 (11.7 %) refused to participate. The participants
had a higher marriage rate (96.7 % vs. 93.8 %, P = 0.005)
and a lower smoking rate (0.3 % vs. 1.6 %, P = 0.003) than
non-participants. Based on their test results, 1392 women
were referred for colposcopy, among which 106 (7.6 %)
refused to return. The women who returned for colpos-
copy (n = 1286) had a lower smoking rate (0.1 % vs. 1.9 %,
P = 0.016) and fewer live births (<3 live births: 91.2 % vs.
84.9 %, P = 0.031) compared to those who refused to
return. For this study, 396 women, with a mean age of
43.7 ± 8.9 years, were recruited from among the women
who were referred for colposcopy. All of the subjects were
married and the average ages of initiation of sexual activity
and menarche were 20.2 ± 2.2 years and 15.5 ± 1.7 years,
respectively. More than half of the women (56.5 %) re-
ported primary school as their highest educational level,
33 % reported middle school, and only 10.5 % reported
high school or college education. The majority were
farmers or housewives (73.5 %), non-smokers (99.3 %),
and non-drinkers (86.4 %). Ninety-seven percent (96.9 %)
of the women reported having three or less sexual part-
ners, 62.7 % had three or less pregnancies, and 85.4 % had
three or fewer live births (Table 1).
Pathological confirmation and valid cases
Of the 396 samples, 17 were used for careHPV™ pilot test-
ing. In addition, eight FTA card samples and three DCM
samples did not provide valid results for the Cobas® 4800
test. Therefore, our final analysis was conducted using 368
samples that had valid results for all three HPV tests.
Specifically, 34 cases were diagnosed as CIN Grade 1
(CIN1), nine as CIN Grade 2 (CIN2), two as CIN Grade 3
(CIN3), and one case as High Grade Cervical Glandular
Intraepithelial Neoplasia (HCGIN).
HPV positivity and accuracy of detecting CIN2+ for
different screening methods
VIA showed a high specificity (95.8 %) for detecting
CIN2 or worse (CIN2+) lesions, but a low sensitivity
(8.3 %). Only one of 12 CIN2+ cases was identified by
VIA. HPV prevalence and the accuracy of detecting
CIN2+ lesions for six combinations of two sampling
mediums with three HPV testing methods are shown in
Table 2. The liquid samples showed comparable HPV
positivity among HC2 (30.4 %), careHPV™ (28.8 %) and
Cobas®4800 (32.1 %) tests. Compared to the liquid sam-
ples, FTA-based samples showed lower HPV positivity
for HC2 (22.8 %) and careHPV™ (23.9 %), but a higher
HPV positivity for Cobas®4800 test (39.4 %). The FTA card
evidenced higher specificity for the HC2 test compared to
Wang et al. BMC Cancer  (2015) 15:848 Page 4 of 8
the liquid medium (79.5 % vs. 71.6 %, P = 0.015), but a
relatively lower specificity for the Cobas®4800 test (62.4 %
vs. 69.9 %, P = 0.032). For the careHPV™ test, two sam-
pling methods demonstrated comparable specificity (FTA
vs. Liquid: 78.1 % vs. 73.0 %, P > 0.05). For the other accur-
acy parameters, FTA and the conventional DCM sampling
medium provided comparable results. Specifically, the
FTA card demonstrated a sensitivity identical with that of
the DCM medium for HC2 (91.7 %), careHPV™ (83.3 %),
and Cobas®4800 test (91.7 %). Moreover, with similar
negative predictive value (NPV), the FTA card showed
comparable positive predictive values (PPV) for HC2
(FTA vs. Liquid: 13.1 % vs. 9.8 %, P = 0.47), careHPV™
(FTA vs. Liquid: 11.4 % vs. 9.4 %, P = 0.66), and
Cobas®4800 (FTA vs. Liquid: 7.6 % vs. 9.3 %, P = 0.61)
tests.
Detection results of individual analyses for 12 CIN2+
cases are shown in Table 3. The results showed that the
HC2 and careHPVTM tests failed to identify one and two
CIN2+ cases, respectively. The Cobas®4800 test identified
all the CIN2+ lesions except for one case of HCGIN. We
also calculated the overall percent agreement of three HPV
testing methods between two sampling mediums. The
results showed a good overall percent agreement of 90.2 %
(95%CI: 87.2–93.3 %), 83.7 % (95%CI: 79.9–87.5 %), and
85.6 % (95%CI: 82.0–89.2 %) between FTA card and liquid
based sampling methods for HC2, careHPV™, and
Cobas®4800 tests, respectively (Table 4).
Discussion
According to our results, compared to current liquid-
based HC2 testing, using FTA cards significantly increases
test specificity while maintaining comparable sensitivity.
These test characteristics could greatly reduce the referral
rate for colposcopic examinations. Moreover, FTA cards
provided comparable accuracy compared to the liquid-
based medium for careHPV™, thereby providing an alter-
native sampling method for cervical cancer screening in
remote areas. For the Cobas®4800 tests, FTA card-based
samples showed a higher HPV positivity and a lower spe-
cificity of detecting CIN2+ compared to liquid samples.
Further optimization of the workflow for the Cobas®4800
test is required to reduce false positives.
The combination of FTA cards with HC2 tests was pre-
viously explored in Holland [10]. Our study demonstrated
a better overall percent agreement (China vs. Holland:
90.2 % vs. 77.4 %) between FTA cards and the liquid
medium and a higher sensitivity for CIN2+ detection






(%) Sensitivity Specificity Positive Predictive Value Negative Predictive Value
% (n/N) 95 % CI % (n/N) 95 % CI % (n/N) 95 % CI % (n/N) 95 % CI
HC2 FTA 22.8 91.7 (11/12) 76.1 ~ 100.0 79.5 (283/356) 75.3 ~ 83.7 13.1 (11/84) 5.9 ~ 20.3 99.6 (283/284) 98.9 ~ 100.0
Liquid 30.4 91.7 (11/12) 76.1 ~ 100.0 71.6 (255/356) 66.9 ~ 76.3 9.8 (11/112) 4.3 ~ 15.3 99.6 (255/256) 98.8 ~ 100.0
careHPV™ FTA 23.9 83.3 (10/12) 62.2 ~ 100.0 78.1 (278/356) 73.8 ~ 82.4 11.4 (10/88) 4.8 ~ 18 99.3 (278/280) 98.3 ~ 100.0
Liquid 28.8 83.3 (10/12) 62.2 ~ 100.0 73.0 (260/356) 68.4 ~ 77.6 9.4 (10/106) 3.8 ~ 15 99.2 (260/262) 98.1 ~ 100.0
Cobas®4800 FTA 39.4 91.7 (11/12) 76.1 ~ 100.0 62.4 (222/356) 57.4 ~ 67.4 7.6 (11/145) 3.3 ~ 11.9 99.6 (222/223) 98.8 ~ 100.0
Liquid 32.1 91.7 (11/12) 76.1 ~ 100.0 69.9 (249/356) 65.1 ~ 74.7 9.3 (11/118) 4.1 ~ 14.5 99.6 (249/250) 98.8 ~ 100.0
95 % CI 95 % confidence interval, FTA Whatman Indicating FTA Elute® card, HC2 Hybrid capture 2
Table 1 Demographic information of the participants
Variable Value
Age (Mean ± SD) 43.7 ± 8.9
Age of sexual debut (Mean ± SD) 20.2 ± 2.2
Age of menarche (Mean ± SD) 15.5 ± 1.7
Marriage (YES, %) 100
Highest education level (%)
Primary school 56.5
Middle school 33





Smoking (NO, %) 99.3
Drinking (NO, %) 86.4
Oral contraceptive (YES, %) 1.9
Sexual partner (n≥ 3, %) 3.1
No. of pregnancies (%)
≤ 3 62.7
> 3 37.3
No. of live births (%)
≤ 3 85.4
> 3 14.6
SD standard deviation and standard error of the mean
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(91.7 % vs. 53.8 %) compared to the Dutch study. Different
workflows, sample sizes and sample utilization may ex-
plain this discrepancy. In this study, FTA card-based sam-
ples were expected to be eluted to HPV concentrations
comparable to those from DCM preservative solution for
the HC2 and careHPV™ assays. However, concentration
discrepancies remained when transferring samples from
solid to liquid, which resulted in a relatively lower HPV
positivity and a higher specificity for FTA card-based sam-
ples. careHPV™ demonstrated a relatively lower sensitivity
than that of HC2, both in our study (careHPV™ vs. HC2:
83.3 % vs. 91.7 %) and in previous studies (careHPV™ vs.
HC2: 90.0 % vs. 96.3 %) [16, 20]. However, considering the
simplicity of sample transportation and storage, lower
costs, and simpler administration, it is nonetheless a
promising tool for future large scale cervical cancer
screening projects, particularly in low resource settings.
Good agreement between liquid-based media and
FTA cards was previously reported for several PCR-
based methods, including GP5+/6+, SPF(10) PCR/DEIA
/LiPA(25), and real-time PCR assays [7, 8, 12]. How-
ever, limited studies have investigated the accuracy of
the combination of FTA cards and PCR-based methods
for CIN2+ detection. A Spanish study showed that the
combination of FTA cards and GP5+/6+ or SPF(10)
HPV testing provided a sensitivity of 95.9–98.0 % and a
specificity of 42.9–48.1 % for CIN2+ detection [11].
Our study is the first to explore the accuracy of FTA
cards in combination with the Cobas®4800 test for CIN2+
detection. As the manufacturer did not provide instruc-
tions for DCM-based sample detection, CICAMS devel-
oped the workflow based on several small pilot studies.
Specifically, samples used for PCR amplification from
FTA cards had a much higher HPV concentration com-
pared to samples from DCM preservative solution (3.6 %
vs. 0.5 %), resulting in a high sensitivity (91.7 %). As a
result, a higher HPV positivity and a lower specificity were
found for FTA card-based samples compared to DCM
samples. Further study is needed to optimize the workflow
for Cobas®4800 testing using FTA card-based samples in
order to reduce false positives and improve the specificity.
Moreover, although this result was comparable with
previous studies (70.97 %) of Cobas®4800 test in China
[21] and other PCR-based methods (42.9–48.1 %) [11],
one needs to take into consideration additional triage
biomarkers in order to reduce the referral rate for





HC2 (Rlu/PC) careHPV™ (Rlu/PC) Cobas® 4800
Liquid FTA Liquid FTA Liquid FTA
447 CIN2 0.20a 181.73 0.42a 17.11 POS POS
445 CIN2 99.90 22.42 51.31 28.50 POS POS
444 CIN3 472.51 650.36 170.00 173.28 POS POS
442 CIN2 675.40 325.26 117.93 140.85 POS POS
448 CIN2 451.36 43.57 104.47 34.00 POS POS
441 CIN2 2003.50 19.03 150.79 37.03 POS POS
446 CIN2 4.26 0.28a 1.39 0.58a POS POS
443 CIN2 463.18 150.22 80.80 89.48 POS POS
450 CIN2 1031.00 92.23 100.65 61.33 POS POS
240 HCGIN 1.05 1.34 0.29a 0.78a NEGa NEGa
288 CIN3 26.62 1.42 20.65 3.71 POS POS
344 CIN2 5.00 50.89 2.68 29.71 POS POS
CIN2 cervical intraepithelial neoplasia grade 2, CIN3 cervical intraepithelial neoplasia grade 3, HCGIN high grade cervical glandular intraepithelial neoplasia, FTA
Whatman Indicating FTA Elute® card, HC2 Hybrid capture 2, NEG negative result, POS positive result, RLU/PC the ratio of relative light units to standard positive
control, cut-point: 1.0
aCIN2+ case failed to be detected
Table 4 Performance and discrepancies between two specimen
storage methods for three HPV testing assays
Test assays FTA
aample
Liquid sample Subtotal Agreement
% 95 % CI
HC2 Positive Negative 90.2 87.2 93.3
Positive 80 4 84
Negative 32 252 284
Subtotal 112 256 368
careHPV™ Positive Negative 83.7 79.9 87.5
Positive 67 21 88
Negative 39 241 280
Subtotal 106 262 368
Cobas4800 Positive Negative 85.6 82.0 89.2
Positive 105 40 145
Negative 13 210 223
Subtotal 118 250 368
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colposcopy. Furthermore, Cobas®4800 testing identified
all of the squamous epithelial lesions but missed one
glandular epithelial lesion (one case of HCGIN). This
reflects the general deficiency of HPV DNA based
screening methods, and need for complementary
cytology.
This is the first report of a study comparing three
downstream HPV testing methods with clinical impli-
cations by FTA cards and conventional liquid based
sampling media. This study explored experimental
workflows for the careHPV™ and Cobas®4800 tests
and optimized the current workflow for the HC2 test,
which provides data for future laboratory investiga-
tions. Moreover, this study differs from previous re-
ports which used PreservCyt (Hologic, Bedford, MA)
medium for a single test; this study is the first to
compare the accuracy of the FTA card and DCM pre-
servative solution combined with three clinical HPV
DNA tests in cervical cancer screening. This study
has some limitations that must be addressed as well.
First, our study was based on a referral population
that was triaged for colposcopy. A higher HPV preva-
lence was found in this group compared to the gen-
eral population, which had an impact on the accuracy
parameters for detecting CIN2+ lesions. Second, this
study is a hospital-based pilot study with a relatively
small sample size. We therefore lacked statistical
power to assess test characteristics among sub-groups.
Third, the Cobas®4800 test workflow requires further
optimization for future large-scale studies. Fourth, we
did not consider the sequence of sample collection.
Taking two samples with a short time interval might
have a negative impact on the accuracy of the second
sample. However, the second sample, which was col-
lected on FTA cards, showed comparable accuracy for
detecting CIN2+. This indicates that FTA cards have a
robust capacity for capturing samples. Future studies
should further evaluate the accuracy of these two sam-
pling media in a random sampling sequence to avoid
any potential bias. Fifth, we made a parallel comparison
for three HPV testing methods on a single FTA card,
which may result in insufficient distribution of sample
for each test. Additionally, reproducibility studies were
not feasible in this study. Finally, there are several types of
cervical cytological sampling brushes, but this study only
used a conical cervical sampler for sample collection. Fu-
ture comparisons of different cytological samplers need to
be investigated to identify the samplers that provide the
highest degree of accuracy.
This work also draws a promising picture for future
large-scale cervical cancer screening projects. As dried
material on a solid carrier is neither hazardous nor con-
tagious, applying genital self-samples on FTA cards can
solve storage and transportation problems encountered
in developing regions. With further optimization and
automation of the experimental procedures, FTA cards
in combination with careHPV™ could be used for cer-
vical cancer screening in remote areas, and FTA cards in
combination with HC2 or Cobas®4800 could be used in
metropolitan areas. Our previous study demonstrated
that the agreement between self-collected and clinician-
collected specimens on FTA cards was very good and
the acceptability of FTA card-based self-collection was
reasonably high [5, 6]. Therefore, future studies should
focus on a feasibility and accuracy evaluation of FTA-
card based self-sampling in cervical cancer screening. It
is possible that, in the future, women will be able to self-
sample at home, and mail the sample to the regional
central laboratory for sample analysis. Doctors would
only call back those with positive result for colposcopic
examination. Consequently, limited healthcare resources
could be focused on high-risk populations, thereby in-
creasing the coverage of current screening initiatives.
Additionally, previous studies demonstrated acceptable
performance of FTA cards in humid tropical climates
with self-collection, which also provides this solid sam-
ple carrier a promising future in cervical cancer screen-
ing in low-resource areas [8, 22].
Conclusions
Our study provided clinical evidence for evaluating the
accuracy of FTA card-based sampling as an alternative to
the liquid-based sampling in cervical cancer screening.
With further optimization of the experimental workflow,
FTA cards can be paired with different HPV DNA testing
methods suitable a variety of economic conditions, thereby
providing new possibilities for large-scale population-based
cervical cancer screening.
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